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A b s t r a c t  
In the present work, an attempt has been made to develop gastro retentive floating tablets of 
Doxofylline. HPMC K4M and carbopol were used as controlled release polymers. All the 
formulations were prepared by direct compression method on 12 station rotary tablet punching 
machine. The blend of all the formulations showed god flow properties such as angle of repose, bulk 
density, tapped density. The prepared tablets were shown good post compression parameters and 
they passed all the quality control evaluation parameters as per I.P limits. FH 5 was the best 
optimized floating formulation because it released drug completely in 12hrs.It was also observed that 
the increasing concentration of polymers had a retarding effect on the drug release from the polymer 
matrices. 
Keywords: Doxofylline, gastric retention, controlled delivery. 
Introduction 
Historically, oral drug administration has been the predominant 
route for drug delivery. During the past two decades, numerous oral 
delivery systems have been developed to act as drug reservoirs 
from which the active substance can be released over a defined 
period of time at a predetermined and controlled rate. From a 
pharmacokinetic point of view, the ideal sustained and controlled 
release dosage form should be comparable with an intravenous 
infusion, which supplies continuously the amount of drug needed to 
maintain constant plasma levels once the steady state is reached 
[1].  
Although some important applications, including oral administration 
of peptide and protein drugs, can be used to prepare colonic drug 
delivery systems, targeting drugs to the colon by the oral route. 
More often, drug absorption is unsatisfactory and highly variable 
among and between individuals, despite excellent in vitro release 
patterns. The reasons for this are essentially physiological and 
usually affected by the GI transit of the form, especially its gastric 
residence time (GRT), which appears to be one of the major 
causes of the overall transit time variability [2].  
Site and time specific oral drug delivery have recently been of great 
interest in pharmaceutical field to achieve improved therapeutic 
efficacy [3-12]. Doxofylline is a member of methyl xanthines 
structurally related to theophylline, used in clinical management of 
patients with obstructive respiratory disorders, in particular Chronic 
Obstructive Pulmonary Disorder (COPD) and Asthma. The 
elimination half life of Doxofylline is 7 hrs which indicated its 
suitability in formulating into a sustained release dosage form.  The 
oral bioavailability of Doxofylline has been reported to be 60%.Due 
to its high solubility in acidic medium (pH 1.2), prolonged gastric 
retention of doxofylline may offer numerous advantages, including, 
increase in the extent of absorption, improved bio-availability and 
therapeutic efficacy. Frequent administration of Doxofylline (400mg 
b.i.d/t.i.d) also prompted to make floating sustained release tablets 
of Doxofylline.  Based on this, an attempt was made through this 
investigation to formulate floating matrix tablets of doxofylline using 
different polymers. The solubility and stability of doxofylline in 
hydrochloric acid helps for better absorption in acidic environment. 
By employing gastro-retentive floating drug delivery systems, the 
dosage form is retained in the stomach and the drug is released in 
a controlled fashion. 
 
Methodology 
 
Doxofylline obtained as a gift sample from Hetero labs Hyderabad. 
HPMC K4M, HPMC K15M  were obtained from Signet Chemical 
Corporation, Mumbai, Avicel pH 101, Lactose Mono hydrate, Conc. 
Hydrochloric acid, Conc. Hydrochloric acid, Aerosil, Sodium 
bicarbonate obtained from S.D. Fine Chemicals, Mumbai. 
Preparation of Doxofylline floating tablets 
The Compositions of different formulation trials with different 
polymers are presented in the Tables 1, 2 and 3. Accurately 
weighed quantities of polymer, avicel were taken in a mortar and 
mixed geometrically. To this mixture required quantity of doxofylline 
was added and mixed slightly with pestle. This mixture was passed 
through 40# and later collected in a plastic bag and blended for 5 
min. To this required amount of sodium bi carbonate was added 
and again mixed for 5 min. Later required quantity of magnesium 
stearate and aerosol were added and the final blend was again 
passed through 40#. Thus obtained blend was mixed thoroughly for 
10 min and compressed into tablets with 13mm x 5mm Caplet 
Punches and corresponding dies at a hardness of 6kg/cm2 on a 
rotary tablet punching machine 
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Table 1:  Formulae used to prepare doxofylline floating tablets with hpmc k4m. 
Ingredients Composition of doxofylline floating tablets (mg) 
 Fh 1 Fh 2 Fh 3 Fh 4 Fh 5 Fh 6 
Doxofylline 600 600 600 600 600 600 
Hpmc k4m 60 120 180 240 300 360 
Avicel 313.5 253.5 193.5 133.5 73.5 13.5 
Nahco3 110 110 110 110 110 110 
Mg.stearate 5.5 5.5 5.5 5.5 5.5 5.5 
Aerosil 11 11 11 11 11 11 
Total weight 1100 1100 1100 1100 1100 1100 
 
Table 2: formulae used to prepare doxofylline floating tablets with hpmc k15m 
 
 
 
 
 
 
Standard Graph of Doxofylline 
An accurately weighed amount of 100mg doxofylline was 
transferred into a 100 ml volumetric flask containing 0.1N HCl to 
dissolve and then the volume was made up to the mark with 0.1N 
HCl. From this necessary dilutions were made to give concentration 
ranging from 1-32 µg/ml solutions. The absorbance of the 
volumetric solutions was recorded at λmax (272nm) of the drug and 
plotted graphically to give the standard graph of doxofylline 
 
Evaluation of Precompression Blend 
 
The powder blend of all formulations was evaluated for Bulk 
density, Tapped density, Compressibility Index, Hausner ratio and 
Angle of repose [5].  
 
Bulk Density 
 
30gms of material was passed through a sieve no. 25 to break up 
agglomerates and introduced into a dry 100mL cylinder, without 
compacting, the powder was carefully leveled without compacting 
and the unsettled apparent volume, Vo, was read. The bulk density 
was calculated, in grams per ml, using the formula. 
                                         (M) / (Vo)  
Where  M = Total  weight  of the powder blend  and V0 is the bulk 
volume of the powder blend 
 
Tapped Density  
 
After carrying out the procedure as given in the measurement of 
bulk density the cylinder containing the sample was tapped using a 
mechanical tapped density tester (Electrolab) that provides a fixed 
drop of 14±2 mm at a nominal rate of 300 drops per minute. The 
cylinder was tapped 500 times initially followed by an additional tap 
of 750 times until difference between succeeding measurement 
was less than 2% and then tapped volume Vf, was measured to the 
nearest graduated unit. The tapped density was calculated, in g per 
ml, using the formula: 
                               (M) / (Vf) 
Where M = Total weight of the powder blend and Vf is the tapped 
volume of the powder blend 
 
Measures of Powder Compressibility 
 
The Compressibility Index and Hausner Ratio are measures of the 
propensity of a powder to be compressed. As such, they are 
measures of the relative importance of inter particulate interactions. 
As such, they are measures of the relative importance of inter 
particulate interactions. In a free-flowing powder, such interactions 
are generally less significant, and the bulk and tapped densities will 
be closer in value. For poorer flowing materials, there are 
frequently greater interparticle interactions and a greater difference 
between the bulk and tapped densities will be observed. These 
differences are reflected in the Compressibility Index and the 
Hausner Ratio, which are calculated using the following formulae 
[9]. 
                      Compressibility Index =   (Vr-Vo) * 100  /  Vr 
                    Where , Vr = Tapped density ; Vo = Bulk density 
Ingredients     composition of doxofylline floating tablets (mg) 
 Fh 7  Fh 8  Fh 9  Fh 10   Fh 11 
Doxofylline 600 600 600 600 600 
Hpmc k15m 60 90 120 150 180 
Lactose 242 212 182 152 122 
Nahco3 102.5 102.5 102.5 102.5 102.5 
Mg.stearate 10.25 10.25 10.25 10.25 10.25 
Aerosil 10.25 10.25 10.25 10.25 10.25 
Total weight 1025 1025 1025 1025 1025 
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Hausner Ratio 
 
It is the ratio of bulk density to tapped density 
                                               Vo/ Vf 
 Vo = Bulk density; Vr= Tapped density 
 
Angle of Repose 
 
The fixed funnel method was employed to measure the repose 
angle. A funnel was secured with its tip at a given height, H above 
a graph paper that was placed on a flat horizontal surface. The 
blend was carefully pored through the funnel until the apex of the 
conical pile just touched the tip of the funnel. The radius, R, of the 
base of the conical pile was measured. The angle of repose, α, was 
calculated using the following formula. 
                                                α = tan-1 H/R 
Determination of Physical Parameters of Floating 
Tablets [10] 
Weight Variation test 
Twenty [20] tablets from each batch were individually weighed in 
grams on an analytical balance. The average weight and standard 
deviation were calculated, individual weight of each tablet was also 
calculated using the same and compared with average weight  
Thickness test 
The thickness in millimeters (mm) was measured individually for 10 
pre weighed tablets by using a Vernier Caliperse. The average 
thickness and standard deviation were reported. 
Hardness test 
Tablet hardness was measured using a Monsanto hardness tester. 
The crushing strength of the 10 tablets with known weight and 
thickness of each was recorded in kg/cm2 and the average 
hardness, and the standard deviation was reported. 
Friability test 
Twenty [20] tablets were selected from each batch and weighed. 
Each group of tablets was rotated at 25 rpm for 4 minutes (100 
rotations) in the Roche friablator. The tablets were then dusted and 
re-weighed to determine the loss in weight. Friability was then 
calculated as per weight loss from the original tablets. 
Determination of Drug Content 
Ten tablets with pre determined weight from each batch were taken 
and crushed in a mortar and weight equivalent to one average 
tablet was taken, transferred to a 250 ml volumetric flask and 0.1N 
HCl was added. The volume was then made up to the mark with 
0.1N HCl. The solution was filtered and the filtrate was sufficiently 
diluted and the absorbance was recorded against the blank at 272 
nm. The drug content of the Standard containing the drug powder 
was also determined. The Drug content was determined by the 
formula [11]. 
              Amount in test 
Drug content =   ------------------------------------ x 100 
       Amount in standard 
The tablet passes the requirements if the amount of the active 
ingredient in each of the 10 tested tablets lies within the range of 
85% to 115% of the stated amount. 
In-vitro buoyancy Studies 
The in-vitro buoyancy (n= 3) was determined by floating lag times 
according to the method described by Rosa et al. The tablets were 
placed in a  beaker containing 100 ml of 0.1N HCL. The time 
required for the tablet to rise to the surface and float was taken as 
floating lag time. Total floating time was also measured.  
 
In vitro Drug Release Studies 
The release rate of Doxofylline floating tablets was determined 
using USP Type 2 Apparatus. The dissolution test was performed 
in triplicate, using 900ml of 0.1N HCL,at 37± 0.5˚C at 50 rpm for 12 
hrs. A 5ml sample was withdrawn from the dissolution apparatus at 
specified time points and the samples were replaced with fresh 
dissolution medium.The samples were filtered through a 0.45-µm 
membrane filter and diluted if necessary. Absorbance of these 
solutions was measured at 272nm using Elico SL -159, U.V-Visible 
Spectrophotometer. Cumulative drug release was calculated using 
the equation (y = 0.03x + 0.024) generated from Beer Lambert’s 
Calibration curve in the linearity range of 1-32µg/ml.  
Kinetic Analysis of Dissolution Data 
To analyze the in vitro release data various kinetic models were 
used to describe the release kinetics. The zero order rate Eq. (1) 
describes the systems where the drug release rate is independent 
of its concentration . The first order Eq. (2) describes the release 
from system where release rate is concentration dependent 8. 
Higuchi 4 described the release of drugs from insoluble matrix as a 
square root of time dependent process based on Fickian diffusion 
Eq. (3). The Hixson-Crowell cube root law Eq. (4) describes the 
release from systems where there is a change in surface area and 
diameter of particles or tablets. 
C = K0 t   (1) 
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Where, K0 is zero-order rate constant expressed in units of 
concentration/time and t is the time. 
 
 LogC = LogC0 - K1 t / 2.303 (2) 
 
Where, C0 is the initial concentration of drug and K1 is first order 
constant. 
 
                 Q = KHt
1/2                    (3) 
 
Where, KH is the constant reflecting the design variables of the 
system. 
 
                  Q0
1/3 – Qt
1/3 = KHC t                                                   (4) 
 
Where, Qt is the amount of drug remained in time t, Q0 is the initial 
amount of the drug in tablet and KHC is the rate constant for 
Hixson-Crowell rate equation. 
 
Standard Graph of Doxofylline 
 
The standard graph of Doxofylline in 0.1N HCl showed a good 
linearity with R2 of 0.999, in the concentration range of 0-32 μg/ml 
at 272nm 
 
 
 
Figure 1 : Standard Graph of Doxofylline in 0.1N HCL 
 
Properties of the Powder Blend 
 
All Formulations were evaluated for Compressibility index, Angle of 
repose and Hausner ratio. The results indicated the pre-
compressed blend gas good flow 
 
 
  Table 4: Flow Properties of The Final Powder Blend 
 
 
 
Evaluation of the prepared tablets for physical 
Parameters 
 
All Formulations were tested for physical parameter like hardness, 
thickness, weight variation, friability and drug content. All estimated 
parameters were found to be within the limits. 
Tablets of all batches had floating lag time below 2 minutes 
regardless of viscosity  and content of HPMC because of evolution 
of CO2 resulting from the interaction between sodium bicarbonate 
and dissolution medium; entrapment of gas inside the hydrated 
polymeric matrices enables the dosage form to float by lowering the 
density of the matrices. It was reasoned that as for HPMC content 
of 10% or more, the particles of HPMC are close enough to permit 
a faster establishment of the gel layer inside which the CO2 gas 
gets entrapped leading to decreased density ultimately leading to 
floating of the tablet . Total Floating time for the HPMC formulations 
were above 12 hrs.  
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Table 5: Physical Parameters Of The Prepared Formulations 
FORMULATION 
       CODE 
 
HARDNESS THICKNESS  
WEIGHT 
VARIATION FRIABILITY 
DRUG 
CONTENT   
(kg/cm2) (mm) (mg) (%) (%)   
FH 1 6.50±0.24 7.384±0.05 1094.60±2.12 0.1 97.23   
FH 2 6.65±0.18 7.276±0.06 1105.33±1.45 0.27. 99.12   
FH 3 6.45±0.37 7.186±0.03 1084.80±1.63 0.19 98.32   
FH4 6.80±0.26 7.186±0.04 1095.09±2.43 0.22 99.54   
FH 5 6.55±0.54 7.234±0.06 1086.05±4.51 0.18 99.43   
FH 6 6.40 ±0.35 7.45 ±0.06 1092.37±3.89 0.21 98.67   
FH 7 6.50±0.48 7.38±0.05 1020.09±4.12 0.16 98.97   
FH 8 6.45±0.25 7.45±0.25 1022.65±4.20 0.16 98.28   
FH9 6.50±0.54 7.50±0.04 1029.15±4.61 0.12 99.43   
FH10 6.50±0.50 7.50±0.07 1030.50±4.39 0.1 98.12   
FH 11 6.20±0.25 7.38±0.02 1021.25±2.68 0.19 99.48   
 
 
Table 6:  in-vitro buoyancy studies. 
 
S.NO 
FORMULATION 
CODE FLOATING LAG TIME  TOTAL FLOATING TIME 
1 FH 1  75    SEC 4hrs  
2 FH 2 82  SEC 6hrs  
3 FH 3 76  SEC 8hrs  
4 FH 4 70  SEC > 12 hrs 
5 FH 5 89  SEC > 12 hrs 
6  FH 6  84  SEC > 12 hrs 
7 FH 7 90  SEC > 12 hrs 
8 FH 8 75  SEC > 12 hrs 
9 FH 9 84  SEC > 12 hrs 
10  FH 10 79  SEC > 12 hrs 
11  FH 11 87  SEC > 12 hrs 
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In-vitro buoyancy Studies of optimized formulation ( FH 5) 
 
 
Figure 2 Invitro buoyancy studies of optimized formulation 
Table 7: cumulative percent drug release of Doxofylline floating tablets with hpmc k4m polymer 
  TIME (HRS)                          CUMULATIVE PERCENT DRUG RELEASE  
 FH 1 FH 2 FH 3 FH 4 FH 5 FH 6 
1 97.85±4.38 75.28±2.87 41.39±2.32 36.6±1.82 27.51±3.38 10.25±2.72 
2 98.65±3.97 98.75±3.14 72.35±2.79 54.9±2.92 37.03±4.81 15.62±1.45 
4 ---- 97.68±3.54 95.86±1.89 70.24±2.14 57.81±1.96 35.47±1.84 
6 ---- 98.21±2.46 97.85±2.38 85.25±3.81 67.54±3.70 58.38±3.72 
8 ---- 98.27±1.97 98.45±5.78 94.2±4.38 79.89±3.18 69.1±3.49 
10 ---- 97.85±4.58 97.94±4.23 99.3±3.47 86.12±2.54 78.36±4.21 
12 ---- 98.75±4.05 99.45±2.64 99.85±1.75 99.28±2.19 86.57±4.19 
 
 
 
FH 5 After    90 sec    FH 5 After 2 hrs 
FH 5 After 6 hrs 
 
FH 5 After  12 hrs 
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Table 8: Cumulative Percent Drug Release Of Doxofylline Floating  Tablets  With Hpmc K15m Polymer 
Time 
(hrs) 
                 Cumulative Percentage Drug Release ±SD 
FH  7 FH  8 FH  9 FH 10 FH 11 
1 41.86±1.57 38.12±1.89 30.31±4.70 18.14±1.26 14.86±0.41 
2 56.72±2.31 48.23±5.21 36.78±3.65 29.93±4.17 21.23±3.16 
4 72.35±3.56 69.54±3.00 56.22±1.98 42.02±3.14 34.86±1.79 
6 77.45±3.70 77.08±1.63 69.92±0.67 55.06±6.52 42.68±1.28 
8 84.34±2.84 84.32±2.91 76.90±2.65 64.12±3.90 55.23±2.33 
10 98.25±3.84 97.25±1.63 86.37±3.7 77.49±4.70 65.38±2.91 
12 97.86±2.14 96.98±4.09 95.49±3.7 81.88±3.47 76.38±2.82 
 
Formulations   FH 1 and FH 2 released the drug completely  within 
2-3 hrs. This was ascertained due to the insufficiency of the 
polymer  to form a rigid gel barrier around the tablet ultimately 
leading to loss of matrix integrity. Increasing the polymer level (FH 
3 formulation) resulted in sustaining the release upto 8-9hrs. FH 4, 
FH 5, and FH 6 formulations released the drug up to 12 hrs but 
only FH 5 formulation was found to release the drug according to 
the predicted theoretical release profile. It shows that increasing 
concentrations of HPMC K15 M polymer has a retarding effect on 
the release of Doxofylline from the matrix tablet.  
The release from the formulations FH 10 and FH 11 was less than 
80% in 12 hrs. The reason expected for this  low release is due to 
incomplete wetting of the matrix by the dissolution medium  which 
was confirmed after 12 hr by scraping off the upper layers of the 
matrix to reveal dry un-wetted core of the tablets.  Among HPMC 
K15M formulations, FH 8 and FH 9 formulations were found to be  
in accordance with the Theoretical release profile. But  among FH 5 
, FH 8 and FH 9 formulations, FH 5 showed greater difference 
factor (f1 = 3) and close similarity factor(f2 =80) when compared 
with predicted theoretical release Profile [27]. Hence FH 5 
formulation was choosen as the best optimized formulation 
 
Table 9: correleation- coefficient ( r2) values of different kinetic models 
 
Formulation  
R
2
 
Peppas 
(n) 
Zero  First  Higuchi  Peppas  
Fh 1 0.598 0.567 0.610 0.785 0.393 
Fh 2 0.612 0.575 0.623 0.815 0.325 
Fh 3 0.608 0.526 0.663 0.805 0.323 
Fh 4 0.817 0.809 0.917 0.972 0.408 
Fh 5 0.927 0.898 0.968 0.995 0.516 
Fh 6 0.961 0.856 0.942 0.989 0.884 
Fh 7 0.926 0.861 0.973 0.984 0.337 
Fh 8 0.931 0.868 0.980 0.987 0.391 
Fh 9 0.972 0.909 0.994 0.990 0.478 
Fh 10 0.981 0.912 0.989 0.996 0.602 
Fh 11 0.991 0.936 0.982 0.992 0.652 
 
It was found out that the optimized formulation FH 5  was best 
explained by the Higuchi’s equation, as the plots showed highest 
linearity (R2 = 0.978),followed by Zero order (R2 = 0.927) and first 
order(R2 = 0.898). This explains why the drug diffuses at a 
comparatively slower rate as the distance for diffusion increases, 
which is referred to as square root kinetics (or Higuchi’s Kinetics).  
To know the mechanism of drug release the dissolution data was 
fitted into Korsmeyer - Peppas equation [20]. It also indicated a 
good linearity (R2 = 0.995) and the release exponent (n) value was 
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found to be 0.56, which appears to indicate a coupling of the 
diffusion and erosion mechanism-so called anomalous diffusion-and 
may indicate that drug release is controlled by more than one 
process. 
 
 Conclusion 
 
Sustained release floating tablets of Doxofylline were successfully 
prepared with hydrophilic polymers like HPMC K4M, HPMC 
K15M.From the Preformulation studies for drug excipients 
compatibility, it was observed that no physical incompatibility 
existed between the drug and excipients. The formulated batches 
were evaluated for physical parameters, floating properties and 
dissolution profiles. The physical properties like weight variation and 
friability of all batches complied with the pharmacopoeial 
specifications. The drug content of all tablets was in the range of 98 
– 102%.From the in vitro dissolution analysis it was found that the 
batches containing HPMC K4M have less retarding capacity than 
with batches containing HPMC K15M. This is because HPMC K4M 
is a low viscosity polymer as compared to HPMC K15M polymer. 
Among HPMC K4M formulations, FH 1 – FH 3 released the drug 
within 2-6 hrs. This is due to insufficient level of polymer to form a 
rigid matrix.  
The optimized formulation among HPMC K4M and HPMC K15M are 
FH 5 and FH 9. These were chosen because of their close similarity 
factor with predicted theoretical release profile. FH 5 was the best 
optimized floating formulation because it released drug completely 
in 12hrs. It was also observed that the increasing concentration of 
polymers had a retarding effect on the drug release from the 
polymer matrices. 
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